336 related articles for article (PubMed ID: 24998423)
41. Carbapenemases and extended-spectrum β-lactamases producing Enterobacteriaceae isolated from Tunisian and Libyan hospitals.
Mathlouthi N; Al-Bayssari C; El Salabi A; Bakour S; Ben Gwierif S; Zorgani AA; Jridi Y; Ben Slama K; Rolain JM; Chouchani C
J Infect Dev Ctries; 2016 Aug; 10(7):718-27. PubMed ID: 27482803
[TBL] [Abstract][Full Text] [Related]
42. High Gastrointestinal Colonization Rate with Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in Hospitalized Patients: Emergence of Carbapenemase-Producing K. pneumoniae in Ethiopia.
Desta K; Woldeamanuel Y; Azazh A; Mohammod H; Desalegn D; Shimelis D; Gulilat D; Lamisso B; Makonnen E; Worku A; Mannerqvist K; Struwe J; Aspevall O; Aklillu E
PLoS One; 2016; 11(8):e0161685. PubMed ID: 27574974
[TBL] [Abstract][Full Text] [Related]
43. Cefepime therapy for monomicrobial bacteremia caused by cefepime-susceptible extended-spectrum beta-lactamase-producing Enterobacteriaceae: MIC matters.
Lee NY; Lee CC; Huang WH; Tsui KC; Hsueh PR; Ko WC
Clin Infect Dis; 2013 Feb; 56(4):488-95. PubMed ID: 23090931
[TBL] [Abstract][Full Text] [Related]
44. National multicenter study of predictors and outcomes of bacteremia upon hospital admission caused by Enterobacteriaceae producing extended-spectrum beta-lactamases.
Marchaim D; Gottesman T; Schwartz O; Korem M; Maor Y; Rahav G; Karplus R; Lazarovitch T; Braun E; Sprecher H; Lachish T; Wiener-Well Y; Alon D; Chowers M; Ciobotaro P; Bardenstein R; Paz A; Potasman I; Giladi M; Schechner V; Schwaber MJ; Klarfeld-Lidji S; Carmeli Y
Antimicrob Agents Chemother; 2010 Dec; 54(12):5099-104. PubMed ID: 20837757
[TBL] [Abstract][Full Text] [Related]
45. Emergence of New Sequence Type OXA-48 Carbapenemase-Producing Enterobacteriaceae in Kuwait.
Jamal WY; Albert MJ; Khodakhast F; Poirel L; Rotimi VO
Microb Drug Resist; 2015 Jun; 21(3):329-34. PubMed ID: 25551428
[TBL] [Abstract][Full Text] [Related]
46. Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-PE) infections: are carbapenem alternatives achievable in daily practice?
Pilmis B; Delory T; Groh M; Weiss E; Emirian A; Lecuyer H; Lesprit P; Zahar JR
Int J Infect Dis; 2015 Oct; 39():62-7. PubMed ID: 26327124
[TBL] [Abstract][Full Text] [Related]
47. Bloodstream infections caused by IMP-8-producing Enterobacteriaceae isolates: the need for clinical laboratory detection of metallo-β-lactamases?
Yan JJ; Lee NY; Chen HM; Wang MC; Ko WC; Tsai LH; Wu JJ
Eur J Clin Microbiol Infect Dis; 2013 Mar; 32(3):345-52. PubMed ID: 23001510
[TBL] [Abstract][Full Text] [Related]
48. Role of Double-Carbapenem Regimen in the Treatment of Infections due to Carbapenemase Producing Carbapenem-Resistant
Cancelli F; Oliva A; De Angelis M; Mascellino MT; Mastroianni CM; Vullo V
Biomed Res Int; 2018; 2018():2785696. PubMed ID: 30581848
[TBL] [Abstract][Full Text] [Related]
49. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital.
Souli M; Kontopidou FV; Papadomichelakis E; Galani I; Armaganidis A; Giamarellou H
Clin Infect Dis; 2008 Mar; 46(6):847-54. PubMed ID: 18269335
[TBL] [Abstract][Full Text] [Related]
50. Correlation of β-Lactamase Production and Colistin Resistance among Enterobacteriaceae Isolates from a Global Surveillance Program.
Bradford PA; Kazmierczak KM; Biedenbach DJ; Wise MG; Hackel M; Sahm DF
Antimicrob Agents Chemother; 2015 Dec; 60(3):1385-92. PubMed ID: 26666920
[TBL] [Abstract][Full Text] [Related]
51. Assessment of the clinical significance of production of extended-spectrum beta-lactamases (ESBL) by Enterobacteriaceae.
Henshke-Bar-Meir R; Yinnon AM; Rudensky B; Attias D; Schlesinger Y; Raveh D
Infection; 2006 Apr; 34(2):66-74. PubMed ID: 16703295
[TBL] [Abstract][Full Text] [Related]
52. A prospective study of treatment of carbapenem-resistant Enterobacteriaceae infections and risk factors associated with outcome.
de Maio Carrilho CM; de Oliveira LM; Gaudereto J; Perozin JS; Urbano MR; Camargo CH; Grion CM; Levin AS; Costa SF
BMC Infect Dis; 2016 Nov; 16(1):629. PubMed ID: 27809803
[TBL] [Abstract][Full Text] [Related]
53. Bacteraemia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge.
Navarro-San Francisco C; Mora-Rillo M; Romero-Gómez MP; Moreno-Ramos F; Rico-Nieto A; Ruiz-Carrascoso G; Gómez-Gil R; Arribas-López JR; Mingorance J; Paño-Pardo JR
Clin Microbiol Infect; 2013 Feb; 19(2):E72-9. PubMed ID: 23231088
[TBL] [Abstract][Full Text] [Related]
54. Clinical significance of extended-spectrum beta-lactamases.
Rodríguez-Baño J; Pascual A
Expert Rev Anti Infect Ther; 2008 Oct; 6(5):671-83. PubMed ID: 18847405
[TBL] [Abstract][Full Text] [Related]
55. Efficacies of colistin and tigecycline in mice with experimental pneumonia due to NDM-1-producing strains of Klebsiella pneumoniae and Escherichia coli.
Docobo-Pérez F; Nordmann P; Domínguez-Herrera J; López-Rojas R; Smani Y; Poirel L; Pachón J
Int J Antimicrob Agents; 2012 Mar; 39(3):251-4. PubMed ID: 22154856
[TBL] [Abstract][Full Text] [Related]
56. Clinical and Bacterial Risk Factors for Mortality in Children With Carbapenem-resistant Enterobacteriaceae Bloodstream Infections in India.
Nabarro LEB; Shankar C; Pragasam AK; Mathew G; Jeyaseelan V; Veeraraghavan B; Verghese VP
Pediatr Infect Dis J; 2017 Jun; 36(6):e161-e166. PubMed ID: 28005691
[TBL] [Abstract][Full Text] [Related]
57. Successful containment of carbapenem-resistant Enterobacteriaceae by strict contact precautions without active surveillance.
Kim NH; Han WD; Song KH; Seo HK; Shin MJ; Kim TS; Park KU; Ahn S; Yoo JS; Kim ES; Kim HB
Am J Infect Control; 2014 Dec; 42(12):1270-3. PubMed ID: 25465255
[TBL] [Abstract][Full Text] [Related]
58. Molecular characterization of intestinal carriage of carbapenem-resistant Enterobacteriaceae among inpatients at two Iranian university hospitals: first report of co-production of bla
Solgi H; Badmasti F; Aminzadeh Z; Giske CG; Pourahmad M; Vaziri F; Havaei SA; Shahcheraghi F
Eur J Clin Microbiol Infect Dis; 2017 Nov; 36(11):2127-2135. PubMed ID: 28639165
[TBL] [Abstract][Full Text] [Related]
59. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control.
Tängdén T; Giske CG
J Intern Med; 2015 May; 277(5):501-12. PubMed ID: 25556628
[TBL] [Abstract][Full Text] [Related]
60. Risk factors for colonization by carbapenemase-producing enterobacteria at admission to a Surgical ICU: A retrospective study.
Maseda E; Salgado P; Anillo V; Ruiz-Carrascoso G; Gómez-Gil R; Martín-Funke C; Gimenez MJ; Granizo JJ; Aguilar L; Gilsanz F
Enferm Infecc Microbiol Clin; 2017; 35(6):333-337. PubMed ID: 27016135
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
